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Abstract This article describes the steps of the develop-
ment and the structure of a disease-specific clinical tri-
als network for cystic fibrosis in Europe. Activities such
as reviewing study protocols, feasibility assessments,
training and standardizing of procedures, and outcome
measurements help to bring high-quality clinical trials to
the patients. Cooperation with the pharmaceutical indus-
try, other research networks, patient organizations, and
regulatory agencies is very important throughout all
activities.
Conclusion: The European Cystic Fibrosis Society—
Clinical Trials Network facilitates the development of new
treatments for a rare disease and could be a prototype for other
diseases.
What is Known:
• Clinical research has led to the first approved treatments targeting the
basic Cystic Fibrosis defect.
• For a rare disease like Cystic Fibrosis, multicenter international
collaboration is needed to obtain solid evidence when testing possible
new treatments.
What is New:
• The Clinical Trials Network established by the European Cystic Fibrosis
Society has grown to a fully operational network with well-defined
structures, procedures and partnerships.
• Standardization of outcome parameters, protocol review, feasibility
assessment and other activities help to develop high quality, efficient,
relevant and feasible clinical trials, with the aim to bring new treatments
to the patients.
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Introduction
Clinical trials networks are large operational groups formed to
facilitate development of new treatments. The cancer research
groups pioneered this initiative [4]. The enormous progress in
survival in nearly every field of oncology is probably the best
testimony to the gain in outcome that can be achieved. Indeed,
when an individual center tackles a research question, the
investigator has access to only a relatively small sample size
and this often does not lead to conclusive evidence [3]. When
clinicians in several centers work together in a structured way
with the aim of prospectively assessing outcome of interven-
tions according to strict research protocols with adequate sta-
tistical power, solid evidence of efficacy or lack of efficacy
can be obtained.
When working in the field of rare diseases, a clinical trials
network becomes evenmore important to facilitate the process
of developing new treatments. It thus seemed logical to devel-
op clinical trial networks for the most common rare disease in
Europe, cystic fibrosis (CF). On the other hand, CF is the most
frequent of the rare disorders and, therefore, a potential proto-
type for other even more rare disease areas. We therefore de-
scribe the path we took to develop a European clinical trial
network dedicated to CF. This initiative can possibly inspire
other learned societies or patient organizations. Therefore, we
further describe how we started, how we grew, and how we
work at present. We also highlight what have been our suc-
cesses and the challenges.
Understand the disease and develop a master plan
Cystic fibrosis affects about 35,000 people in Europe, and
more than 75,000 worldwide. It is a life shortening autosomal
recessive multisystem disorder [14]. At present, in most coun-
tries, the number of adults with CF equals or exceeds the
number of children with CF. But despite a complex treatment,
chronic airway obstruction and infection usually lead to respi-
ratory insufficiency and premature death. Other major mor-
bidity is associated with the gastrointestinal tract. Pancreatic
insufficiency is present in 85 % of subjects, but many other
complications occur like intestinal obstruction, liver disease,
gall stones, etc. Males are nearly always infertile due to vas
deferens obstruction. Salt loss syndromes occur: excessive salt
loss via sweat on hot days can lead to acute dehydration, and
chronic salt depletion can lead to electrolyte abnormalities and
pseudo Bartter syndrome.
Structured follow-up in dedicated centers and guidelines
for optimal treatment were shown to improve outcome [12].
Although steady progress in survival was achieved, the medi-
an age at death in developed countries is still in the late
twenties, mainly due to lung disease. This median age of death
is even earlier when access to specific follow-up and treatment
is difficult [13]. These morbidity and mortality data are gath-
ered from CF registries, including the European Cystic
Fibrosis Society Patient Registry (ECFSPR) [https://www.
ecfs.eu/projects/ecfs-patient-registry/intro]. This registry was
developed around 2000 and now contains data from 35 EU
and non EU countries and more than 29,000 patients [18]. For
rare diseases, registries are critical to learn the natural history
of the disorder, to understand the major morbidities, and to
observe the impact of specific follow up or new treatments.
The discovery of the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) gene in 1989 [15] greatly boosted the
understanding of the basic CF defect. The structure and func-
tion of the CFTR protein as an anion channel was explored, as
was the insight how mutations in the CFTR gene lead to de-
fects in the synthesis (e.g., premature stop codon mutations,
aberrant splice mutations, abnormal CFTR protein trafficking
or folding) or function (abnormal gating or conductance) of the
CFTR protein [17]. The function of the normal CFTR protein
as an anion channel was confirmed as well as its importance in
regulation of other ion channels at the cell surface. Ion channel
dysregulation leads to a decreased height of the periciliary
liquid and abnormal mucociliary clearance which links the
basic CFTR defect to chronic infection and inflammation in
the lung, the major cause of death of patients with CF. As a
consequence of this improved knowledge, the goal within the
CF community became bolder and a master plan on how to
majorly improve outcome for patients with CF by targeting the
basic CF defect was born. Several routes are being explored;
for recent reviews, see [1] and [2]. We succinctly mention the
major strategies. Although initially hoped for, gene therapy did
not prove to be an easy success. Many hurdles need to be
overcome, including the size of the CFTR gene. Directly
targeting the abnormal mRNA may prove more successful.
The development of CFTR modulators, small molecules that
either rescue the misfolded mutated CFTR protein (correctors)
or improve its function at the cell surface by increasing the
gating of the protein (potentiators) has been a more successful
strategy and led to the first approved treatments targeting the
basic CF defect. Stop codon read through drugs are explored
for premature stop codon mutations. Modulating ion channels
other than CFTR is another possible strategy.
In parallel with this drug discovery pipeline, it was obvious
that the clinical phase of drug development needed refinement.
Optimal clinical trial protocols relevant for the patients and
feasible within certain timelines needed to be developed, using
outcome measures that are reliable and standardized between
clinical trial centers. Also, it is important to identify sufficient
numbers of patients with specific characteristics who are moti-
vated and empowered to participate in clinical trials.
818 Eur J Pediatr (2016) 175:817–824
Clinical trial networks for cystic fibrosis
The Cystic Fibrosis Foundation (CFF) in the USA [http://cff.
org/] was the first to develop a CF disease-specific clinical trial
network. They partnered with biotech companies so that they
would take an interest in developing drugs for patients with
CF. For the clinical phase of drug development, they saw the
importance of developing a Therapeutic Development
Network (the CFF-TDN). The therapies or drugs under devel-
opment were grouped according to their place in the patho-
physiologic cascade as well as the phase of clinical develop-
ment: the therapeutic pipeline for cystic fibrosis was born and
the progress over time could bemonitored and easily visualized
[http://www.cff.org/research/DrugDevelopmentPipeline/].
The CFF-TDN was founded in 1998. Several national
European research initiatives came later, as well as a large
Australian CF working group [http://www.arestcf.org/]. In
2009, the European Cystic Fibrosis Society (ECFS) [https://
www.ecfs.eu], a learned society dedicated to CF from research
to care and education, decided to set-up an ECFS—Clinical
Trials Network (ECFS-CTN) [https://www.ecfs.eu/ctn] to
further boost efficient clinical research and speed up the
clinical phase of CF drug development. Know-how and sup-
port by the CFF-TDN greatly boosted the success and rapid
growth of the ECFS-CTN.
The steps needed to start a disease-specific clinical trial
network can certainly be followed by other learned societies
or patient organizations. Therefore, we further describe how
we started, how we work at present, and what have been our
successes and challenges.
Steps in the set-up of a disease specific network
Assess the feasibility of starting a clinical trial network
The learned society ECFS communicated the idea of starting a
disease specific clinical trial network to all of its members and
inquired whether sites in charge of a sizeable numbers of
patients were interested in working together in a clinical trial
network. Of 139 replies, 127 were positive and 95 centers with
more than 100 CF patients under their care were identified.
Hereby, feasibility was established.
Given the many candidate sites, criteria for site participa-
tion and site ranking were set up. These included patient po-
tential, meeting the ECFS standards of care for patients with
CF [11], having experience with clinical trials, having the
available staff and infrastructure, know-how on specific mea-
surement techniques for use in clinical trials, having a detailed
CF patient database, agreeing to reserve the patient population
for clinical trials run by the network, and demonstrating insti-
tutional support for working in this network.When the call for
joining the clinical trials network was launched, 29 applica-
tions were received from candidate sites. From these, 18 sites
in 8 different countries were selected according to the pre-
defined criteria by an independent committee including scien-
tists experienced with other disease specific clinical trial
networks.
Apart from learned societies for CF, several countries, in-
cluding many European countries, have one or more patient/
parent support group. From the conception of the idea of a
disease-specific network, the learned society ECFS informed
the patient organizations (grouped in CF Europe [http://www.
cf-europe.eu/]) about this plan and sought their cooperation as
a partner to develop this plan.
Outline the global network structure
With many partners involved, the setup of an executive com-
mittee that steers the activities via a coordinating center was
considered crucial. The need for additional committees in
charge of specific tasks was also anticipated (Fig. 1).
The executive committee develops and adapts the global
strategies of the network. It is chaired by the CTN director
who presides the two weekly teleconferences with a
preplanned agenda. Members of the executive committee are
elected for 3-year terms and represent different European
countries. The CTN director is also appointed for 3 years.
He or she is a CF physician from one of the participating sites.
The CTN director is assisted in his function by the co-chair
and the additional personnel at the coordinating center. The
latter is responsible for the day to day activities of the network.
The coordinating center manages the continuous contact with
all CTN sites: feedback, requests, etc. Executive committee
meeting minutes are prepared at the coordinating center and
sent to all investigators as well as to CF patient organization
representatives.
Twice a year, all partners in the network meet face to
face. This steering committee includes one investigator
from every participating site, all members of the exec-
utive committee, leaders of the additional committees,
and representatives of national CF patient organizations.
Updates on all network activities are provided. Prior to
this meeting, new policies or action plans are prepared.
These are then discussed, if necessary amended and
agreed upon. A representative of the American CF net-
work (CFF-TDN) is also invited to these meetings. This
is an enormous boost to keep both networks aligned, to
avoid duplication, to use all expertise available.
Financially, the network is supported by the ECFS and by
some national patient parent organizations united in CF
Europe. A small income is also derived from companies
through the review of protocols or feasibility checks.
Specific funding is asked for specific projects. For example,
a funding from the CFF was received to assess and improve
the quality of the network.
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Mission and core tasks of a disease specific clinical trial
network
The ECFS-CTN has a mission to speed up and improve the
quality of the clinical phase of drug development. This is done
by striving for optimal clinical trial protocols, experienced
clinical research practice in every participating site, rigorous
standardization of outcome measures, and access to large pa-
tient cohorts familiar with clinical research. ECFS-CTN does
not work as a contract research organization (CRO) and is as
such not responsible for the actual running or quality control
in individual sites. It is however important to critically review
candidate studies assessing the study design, choice of out-
come parameters, feasibility, and priority. It is also of the ut-
most importance to standardize how the CF-specific outcome
measures will be assessed and to offer and monitor site train-
ing in clinical trials.
Below, we describe the core tasks. Specific committees are
responsible for specific tasks: protocol review, standardization,
training, and networking. There is an independent data safety
monitoring board (DSMB). Teleconferences of individual com-
mittees are organized at regular intervals. Wherever possible,
we align our strategy with that of the CFF-TDN in the USA.
Protocol review
All clinical trials that are intended to run within the network are
first reviewed via the protocol review committee. To facilitate a
swift process, this work is performed by four permanent review
groups all including CF specialists, a study coordinator, a stat-
istician, and a CF patient or parent. All score the protocol for
scientific merit, feasibility, study design, and strategic fit. A
summary report is written by the primary reviewer. There is a
possibility to have a combined review with the American net-
work (CFF-TDN) for clinical trials that are planned to be con-
ducted in Europe as well as in North America. After protocol
review, the executive committee votes on the acceptance of the
protocol to be run within the network.
As a network policy, the sites agree that by being part of the
ECFS-CTN, they only conduct international industry-sponsored
studies that have been reviewed and approved by the ECFS-
CTN. Since 2009, 57 protocols have been reviewed, 54 have
been industry-sponsored, and 3 were investigator-initiated trials.
As years evolve, we notice that protocols are submitted to
CTN at an earlier stage and that the ECFS-CTN impact on
protocol development is increasing. Sponsors more frequently
provide a revised protocol for a second review step,
implementing suggestions from the initial review and gaining
a better score on the scientific merit and strategic fit.
The number of active studies in the network has increased
with every consecutive year and now fluctuates around 15
active studies running simultaneously.
Protocol feasibility assessment
The ECFS-CTN has disease-specific knowledge and can help
companies develop a relevant feasibility questionnaire. The
clinical sites will provide an accurate count of the number of
patients meeting specific study eligibility criteria by consult-
ing their patient databases, which will help the company for
appropriate site selection. This way, useless and complex ad-
ministrative questions are left out so that sites are not burdened
unnecessarily.
Since 2011, the network provides this service that is cen-
tralized by the CTN coordinating center and can take place in
parallel with the protocol review. This service has been per-
formed for 28 protocols since then.
Standardization of clinical trial outcome parameters
In addition, by harmonizing how an outcome measure is used
in different centers via unambiguous standard operating
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procedures, there will be less variability in results and, there-
fore, treatment benefit can be evaluated in a more reliable way.
In addition, a lower patient number will need to be included in
the clinical trial to reach the same statistical power. The stan-
dardization committee has put a great effort in standardizing
measurement of outcome parameters via separate working
parties, each specific to one type of outcome and standardized
operating procedures (SOPs) have been written for all CF-
specific outcome measures. The SOPs are available upon re-
quest at the coordinating center and are of great interest for
pharmaceutical companies. Moreover, all sub-committees
have worked via a similar, effective method by inventorizing
all available information on the clinimetrics of CF-specific
outcome parameters, identifying gaps in knowledge, and pub-
lishing the findings in major journals [6, 9, 10].
The European Medicine Agency (EMA) has expressed in-
terest in this work. In 2012, it organized a workshop on out-
come measures for clinical trials in CF [https://www.ecfs.eu/
files/webfm/webfiles/File/documents/EMA_Workshop2012.
pdf]. This discussion was urgently needed because the only
surrogate outcome parameter currently approved (forced
expiratory volume in 1 s or FEV1) is no longer a sensitive
endpoint in a population with a continuously improving long-
term outcome [5]. Therefore, the ECFS-CTN is rolling out two
new endpoints and, in addition, has organized central reading
for these: multiple breath washout with asmain readout the lung
clearance index (a more sensitive lung function technique es-
pecially useful in early or mild lung disease) and an imaging
endpoint (chest computed tomography). A procedure for cen-
tralized reading is also available for CFTR biomarkers.
Again, all work on outcome parameters has been made
easier by the work already done by the CFF-TDN, and the
ECFS-CTN has worked in harmony and close collaboration
with the CFF-TDN.
Training committee
The training committee is promoting the improvement of
knowledge and skills in clinical research of all investigators
and research coordinators. This is achieved by organizing a
yearly training session. Different topics are approached every
year, and a mixture of ex cathedra and interactive sessions is
used. To maximize interest and learning, topics suggested by
investigators or research coordinators are included. New
themes are approached like preparing for an audit, site trial
cost calculation, etc. Making sure all members have up to date
Good Clinical Practice (GCP) certification and listing/
promoting learning sources are other tasks.
Other committees and activities
Networking with other learned societies, relevant clinical trial
networks, regulatory authorities, and other possible partners is
the ongoing task of the networking committee. The ECFS-
CTN is part of the coordinating group of the EMA’s network
for pediatric research (EnprEMA) [http://www.ema.europa.
eu/ema/index.jsp?curl=pages/partners_and_networks/general/
general_content_000303.jsp&mid=WC0b01ac05801df74a].
A data safety monitoring board (DSMB), working inde-
pendently from the network, is available upon request of
pharma companies.
Another action point is to convince companies to supply
placebo arm data from previous CF clinical trials so that the
natural variability of outcome parameters can be described.
This information is useful for planning of future studies, es-
pecially for power calculations and deciding on number of
patients needed to include in a trial. It is encouraging that
pharmaceutical companies increasingly see the value of shar-
ing data with academic investigators and works towards more
openness and even full disclosure of research results [8].
The ECFS-CTN sites have access to a yearly report on
study performance including patient enrolment in clinical
trials, other clinical trials metrics, and site responsiveness
to various ECFS-CTN queries. The scores are given in an
individual anonymized way allowing sites to benchmark
their performance against the other sites. Those assessments
are intended to help sites identify areas to target for im-
provement. An online quality improvement program was
developed by the CFF-TDN and shared with the ECFS-
CTN. It consists of several steps, from self-assessment to
identification of areas of improvement and tools to drive
changes at site level.
Partnership with national patient organizations
The European National CF Associations provide a small
financial support to the network. They are represented in
the executive and steering committees. The network tries
to involve patients and patient organizations as much as
possible because active clinical trial enrolment is only pos-
sible via empowerment of the patients. During protocol re-
view, patients (or parents of patients) give their view on
aspects that they are the expert on. They answer questions
on the acceptability of the burden of the experimental pro-
tocol, check if the visit schedule is acceptable to patients
who will be recruited in the study, and whether the planned
procedures are familiar to the study population. Also, they
are asked for suggestions on how to make the protocol pro-
cedures more feasible for potential subjects. The patient re-
viewers are trained on clinical trial regulations, study design,
and study protocol rules.
Patient empowerment is also promoted via a brochure
explaining different aspects of clinical trials. Leaflets specific
for children about participation in clinical trials are available.
In addition, the interest in clinical trials is boosted by educa-
tional leaflets explaining how their current medications have
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been developed. All mentioned documents are freely available
on the ECFS-CTN website [https://www.ecfs.eu/ctn/patient-
brochures]. In the near future, it is planned to setup an
advisory group for young persons with CF.
Successes and challenges
Successes
The ECFS-CTN was quickly successful and popular. The mo-
tivation to join was very high, and already in 2012, the net-
work expanded to include an additional 12 sites out of 37
further applicants. A new expansion (wave 3) has become
operational in 2016. The network now counts 34 sites in 15
countries grouping 17,500 patients. An up-to-date list of cen-
ters and investigators who participate in the network is pub-
licly available on the ECFS-CTN website [https://www.ecfs.
eu/ctn/list-ctn-centres].
The ECFS-CTN have achieved much in a short time
period. The ECFS-CTN has become very operational and
productive despite having limited financial resources. This
was possible thanks to a head-start by the CFF-TDN
allowing us to use all of their expertise. The enthusiasm of
investigators and research coordinators within the network
has been the catalyzer of this fast progress. Every member
feels involved because responsibilities are rotated on a pre-
defined basis. Many new activities have started involving
new partners so that all feel imbedded and active in the
network. All partners feel that their expertise and experience
in clinical trials has improved noticeably. All strive for op-
timal quality delivery.
The network provides specific expertise and advice to
companies conducting CF clinical trials. The network also
offers high quality in clinical trials via the work done in
experienced and well trained sites. Investigators and pa-
tients are aware that the clinical trials conducted via
ECFS-CTN have been reviewed and meet certain standards.
During trial startup and conduct of a trial, the ECFS-CTN
central office stays in close contact with all sites. The net-
work can therefore identify issues for improvement and can
act as a single point of contact to sponsors until resolution
of problems.
It has never been the intention of the ECFS-CTN to mo-
nopolize clinical trials in the field of CF in the network sites.
The aim is to improve the quality of CF trials and to intensify
clinical research in the area of CF. However, because the net-
work now provides access to 17,500 patients in 15 countries
(more than half of known subjects with CF in Europe),
bypassing the network becomes difficult for any international
CF-related clinical trial.
We have been able to standardize outcome measures and
we had fast recruitment for CF studies, especially for trials
with CFTR modulators.
Challenges
Running an investigator-initiated clinical trial
The network feels that all elements are in place to start
an investigator-initiated trial. There is a need: the many
unanswered CF treatment questions including trials in the
area of comparative effectiveness that will unlikely be
evaluated by an industry sponsor. There is the necessary
network capacity: patient numbers, expertise for appro-
priate protocol design, standardized outcome parameters,
the investigators’ willingness to perform these types of
trials.
Although in the past years, an orderly process was followed
for the topic selection and protocol development, so far no
ECFS-CTN investigator-initiated study has started. This is
mainly because of complexities associated with different reg-
ulations in different countries, and with feasibility. Also, it is a
challenge to find the necessary budget for an Europe wide
study.
Regulations and administrative burden surrounding
clinical trials
We are very enthusiastic about the response of the European
Medicine Agency to our network. We had a successful meet-
ing on outcome parameters, and all were convinced that a new
and modernized view on outcome parameters is needed.
However, so far, this has not resulted in specific actions by
the EMA. The Pediatric Investigation Plan is a good initiative
but sometimes leads to unrealistic requests for trials that are
not feasible.
We do see that there is overregulation for low-risk clinical
trials such as academic studies of comparative effectiveness.
This is an obstacle. Overregulation also moves the focus away
from patient safety to an overload of administrative work [7].
It unnecessarily increases cost for these trials. In many coun-
tries trials in the comparative effectiveness area require that
drugs are supplied to the patient via the study budget. This is
unreasonable since the patient would also be treated if not
included in the trial.
Finances
Although the national patient organizations support the net-
work intellectually, very little financial support is brought in.
This is to some level understandable because the patient orga-
nizations raise money on a national level and very little of this
money is allowed to cross the border. Still for research and
clinical trials in a rare disease such as CF, the solution is really
at a multinational level. The American network does not have
that particular challenge.
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The ECFS-CTN actively chooses not to be financially de-
pendent on pharmaceutical companies, CROs, and other com-
mercial vendors. Our motivation to invest in drug develop-
ment is to improve patient outcome via faster access to new
and better treatments. We therefore do not want to make a
great profit from working with companies. On the other hand,
we do realize that the ECFS-CTN does facilitate their work.
Still, we have absolutely no influence on pharma drug cost
setting nor on necessary Beasy^ to implement safety measures
such as the need of cumulative lab results during the conduct
of clinical trials. We do not have much influence also on the
choice of European countries where a study will run as this is
usually decided very early on by a company. This results in
having experienced sites underused because they belong to
what companies perceive as insufficiently appealing countries
for whatever the reason.
In contrast with other networks, sites selected to be part
of the ECFS-CTN get no funding because there are insuf-
ficient resources in the network. They are involved in a
very stimulating collaborative work, and they have more
opportunities to run studies which bring some funding.
However, they are dependent on their national or institu-
tional clinical research programs and the ECFS-CTN is
unable to help selected sites to become even more efficient
with additional human resources or to develop some spe-
cific outcome measures by helping them acquire the equip-
ment or the expertise.
Access to appropriate research funding is difficult as the
competition is stiff. There is also no proper alignment between
the setting of priorities in research and the assignment of nec-
essary EU funding, e.g., the European Medicines Agency put
out a document listing the research priorities to diminish cur-
rent unlicensed and off label use of drugs in children [16]
[http://www.ema.europa.eu/docs/en_GB/document_library/
Other/2009/10/WC500004017.pdf]. But this work and listing
was never followed up by providing the necessary funding to
bring this plan forward.
Conclusion
Disease-specific clinical trial networks are especially impor-
tant in rare disorders. Clinical trial protocol review and stan-
dardization of outcome parameters can form the core towards
improved clinical trials with robust outcomes. In addition, an
increased level of knowledge by all participants in the network
further improves quality delivery. Around the core commit-
tees, other activities can be built such as networking, data
safety monitoring, quality control, and self-evaluation.
Thanks to a lean but very performant central coordination
team much can be achieved at a limited cost. Acquiring better
funding for investigator-initiated trials is one of the priorities
of the network.
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